Movianto Slovensko s.r.o
Movianto Slovensko s.r.o is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib (LOU064) in adult chronic spontaneous urticaria patients who completed the preceding remibrutinib Phase 3 studies.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Movianto Slovensko s.r.o?
The 2026-10-09 snapshot links Movianto Slovensko s.r.o to 8 distinct CTIS trials. Recorded services include Medicinal product management, Destruction and storage of returned study medication, Destruction of the investigational medicinal products, Drug storage, distribution, and destruction, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Movianto Slovensko s.r.o?
The most frequently recorded therapeutic areas are Cardiology, Immunology, Allergy, Dermatology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Movianto Slovensko s.r.o conducted?
The linked trials record locations in 25 countries, including Slovakia, Czechia, France, Italy, Bulgaria. These are trial locations, not confirmed office locations or countries where Movianto Slovensko s.r.o delivered services.
What can this page tell me about Movianto Slovensko s.r.o's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Movianto Slovensko s.r.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Movianto Slovensko s.r.o.